n,n-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine has been researched along with ergoline in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hansen, HA; Mulder, AH; Schoffelmeer, AN; Stoof, JC | 1 |
1 other study(ies) available for n,n-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine and ergoline
| Article | Year |
|---|---|
Blockade of D-2 dopamine receptors strongly enhances the potency of enkephalins to inhibit dopamine-sensitive adenylate cyclase in rat neostriatum: involvement of delta- and mu-opioid receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenylyl Cyclase Inhibitors; Animals; Benzazepines; Corpus Striatum; Cyclic AMP; Dopamine; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Enkephalins; Ergolines; Male; Morphine; Naloxone; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, mu | 1986 |